WHO ICTRP trial
A 24-week open-label, multicenter, follow-up and extension study to…
EUCTR2009-012316-40-GB · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2009-012316-40-GB |
|---|---|
| Public title | A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab at the time of gout flare. - H2251E1 |
| Scientific title | A 24-week open-label, multicenter, follow-up and extension study to CACZ885H2251, to assess safety, tolerability and efficacy of canakinumab (ACZ885) in patients with gout who are given canakinumab at the time of gout flare. - H2251E1 |
| Primary sponsor | Novartis Pharma Services AG |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Countries | Hungary;Portugal;Germany;Czech Republic;Slovakia;United Kingdom;Spain |
| Conditions | Acute flares of gout MedDRA version: 9.1 Level: LLT Classification code 10064900 Term: Gout flare |
| Interventions | Product Name: Canakinumab Product Code: ACZ885 Pharmaceutical Form: Powder for solution for injection INN or Proposed INN: Canakinumab Current Sponsor code: ACZ885 Other descriptive name: Recombinant human monoclonal antibody to human… |
| Registration date | Jun 18, 2009 |
| Secondary IDs | CACZ885H2251E1 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: